Elsevier Delivers Unified Medication Management Platform in China
Shanghai, China, December 12, 2013
Innovative clinical decision support application an
example of U.K.-Sino collaboration to drive localized solutions
for improved medical, health and patient care
Innovative clinical decision support application an example of U.K.-Sino collaboration to drive localized solutions for improved medical, health and patient care
Elsevier, a world-leading provider of
scientific, technical and medical (STM) information products and services, and
part of the Reed Elsevier group, announced today that it has successfully
deployed the unified clinical medication decision support solution, known as Clinical Medication Decision Support All
(CMDS- All), at The First Affiliated
Hospital of Soochow University in Suzhou, Jiangsu
Developed by Shanghai Datong Medical Information Technology Co. Ltd. (Datong), a fully-owned Elsevier entity that focuses on delivering localized solutions for drug-related decision support, CMDS-All integrates previously disparate medical and pharmacological applications into a single solution platform with additional functionalities of prescription and analytics solutions.
"This milestone development leverages our strong U.K.-Sino relationship that pairs Elsevier's suite of quality international medical content and advanced technology with local expertise to deliver innovative customized solutions that address specific market needs," said Ron Mobed, Elsevier's Chief Executive Officer. "Elsevier's strategy of targeted investments has led to the creation of innovative products, solutions and services that serve to elevate the standard of health services for local communities."
CMDS-All is deployed as an end-user application software solution supported with a backend system that provides real-time information and alerts. These are based on analytical processing of integrated content such as patient information, patient prescription history, drug-related database and health information systems to deliver real-time medication decision support to clinicians and health care providers.
Through an integrated medication solutions platform, CMDS-All offers medical and health care institutions the advantages of:
- Greater operational efficiencies for healthcare providers from better utilization of resources through consolidation of multiple disparate applications into a single integrated system such as basic patient information, electronic medical records, laboratory information systems and prescription histories
- Improved and faster responsiveness through a central monitoring and alert system integrating critical medical, drug-related and patient information as well as health information systems
- More comprehensive and greater prescription accuracy through medication analytics to avoid drug-related errors and malpractices
- Improved and better hospital and patient management through real-time monitoring and drug administration resulting in better health and patient care
"Continuous reforms in China's health care sector are requiring medical and health organizations to provide safer, faster and more efficient medical services with greater accuracy for better patient care, and CMDS-All is the one-stop clinical medication decision support system that addresses those needs," said Yukun Harsono, Managing Director of Elsevier for Greater China. "CMDS-All is the enabling solution that is able to deliver the right information to clinical practitioners at the right time to make the right decision for the best outcomes."
# # #About Elsevier
Elsevier is a world-leading provider of information solutions that enhance the performance of science, health, and technology professionals, empowering them to make better decisions, deliver better care, and sometimes make groundbreaking discoveries that advance the boundaries of knowledge and human progress. Elsevier provides web-based, digital solutions — among them ScienceDirect, Scopus, Elsevier Research Intelligence, and ClinicalKey — and publishes nearly 2,200 journals, including The Lancet and Cell, and over 25,000 book titles, including a number of iconic reference works.
The company is part of Reed Elsevier Group PLC, a world leading provider of professional information solutions in the Science, Medical, Legal and Risk and Business sectors, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).
Director, Corporate Relations, Asia Pacific
+65 634 902 40